Key Developments: Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

15 Aug 2014
Price Change (% chg)

€-1.90 (-2.93%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Merck KGaA announces positive outcome of IIIb study for Kuvan
Wednesday, 23 Apr 2014 08:00pm EDT 

Merck KGaA:Announces Phase IIIb SPARK study has met its primary endpoint.Results of first 26 weeks of study showed that addition of Kuvan (sapropterin dihydrochloride) to phenylalanine-restricted diet in children less than 4 years of age who have phenylketonuria (PKU) and have been shown to be responsive to Kuvan significantly increased tolerance to phenylalanine.This is in comparison with phenylalanine-restricted diet alone.SPARK is Phase IIIb, multicenter, open-label, randomized, controlled study designed to assess efficacy, safety, and population pharmacokinetics of Kuvan in patients younger than 4 years old with PKU and who have been previously shown to be responsive to Kuvan in response test.  Full Article

Oncothyreon announces Merck KGaA initiates phase 3 START2 study with Tecemotide in stage III non-small cell lung cancer
Monday, 7 Apr 2014 06:00am EDT 

Oncothyreon Inc:Says Merck KGaA initiates international Phase 3 START2 study, designed to assess the efficacy and safety of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide in patients with unresectable, locally advanced Stage III non-small cell lung cancer (NSCLC).Merck KGaA, Darmstadt, Germany, is developing tecemotide under a license agreement with Oncothyreon.Merck KGaA, Darmstadt, Germany, obtained the exclusive worldwide rights for development and commercialization of tecemotide from Oncothyreon Inc.  Full Article

Merck KGaA issues FY 2014 outlook in line with analysts' estimates
Wednesday, 5 Mar 2014 07:00pm EST 

Merck KGaA:Expects slight increase in organic sales for FY 2014.Says however, growth is likely to be offset by continued negative foreign exchange effects.Expects as consequence stable sales in FY 2014.Expects to again achieve the 2013 level of EBITDA pre one-time items in FY 2014.FY 2013 sales of 10,700.1 million euros.FY 2014 revenue estimate 11,192 million euros - Thomson Reuters I/B/E/S.FY 2013 EBITDA (pre one-time items) of 3,253.3 million euros.FY 2014 EBITDA estimate 3,305 million euros - Thomson Reuters I/B/E/S.  Full Article

Merck KGaA announces resignation of CFO
Sunday, 26 Jan 2014 03:41pm EST 

Merck KGaA:Announces that Merck Group Chief Financial Officer Matthias Zachert has received the offer to be appointed as Chief Executive Officer of Lanxess AG and he therefore asked for an early release of his duties.Says company will accept this request.  Full Article

Eurofins Scientific SE acquires Discovery and Development Solutions business of Merck KGaA
Thursday, 9 Jan 2014 01:30am EST 

Eurofins Scientific SE:Announces the signing of an agreement to acquire the assets of the Discovery and Development Solutions (DDS) business of Merck Millipore (EMD Millipore in the United States and Canada), the Life Science division of Merck KGaA, Darmstadt, Germany.Says it will retain DDS' workforce and leadership, and the business will continue to be led by Christina Shasserre.Says the company's name will be changed to Eurofins Pharma BioAnalytical Services.No further details were provided.  Full Article

Merck KGaA enters into license agreement with Spanish National Cancer Research Centre
Wednesday, 18 Dec 2013 10:00am EST 

Merck KGaA:Says a license agreement has been signed with the Spanish National Cancer Research Centre (CNIO) in Madrid in the area of cancer drug development.Says under the terms of the license agreement, CNIO has granted to Merck exclusive rights to develop and commercialize their new inhibitors of the ataxia telangiectasia and Rad3-related (ATR) kinase.Says in exchange, Merck will make an initial payment along with other potential income of up to nearly 19 million euros, as well as royalties on net sales.  Full Article

Merck KGaA reaches agreement on recommended cash offer for AZ Electronic Materials SA
Thursday, 5 Dec 2013 02:00am EST 

Merck KGaA:Says it reached an agreement with the Board of Directors of AZ Electronic Materials SA (AZ) regarding a recommended cash offer for the entire share capital of AZ.Says according to the terms of the agreement, Merck is offering 403.5 pences per share of AZ in cash, valuing AZ at around 1.6 billion punds (around 1.9 billion euros).Says offer represents a premium of around 41 percent over the 3-month volume-weighted average share price of AZ.Says the Board of Directors of AZ intends to recommend that the company's shareholders accept the offer and the directors have irrevocably undertaken to tender their own shares (representing approximately 0.7 percent of the issued share capital of AZ).Says acquisition will be 100 percent financed by existing cash resources.Says successful completion of the transaction is among others conditional upon antitrust clearance as well as a minimum acceptance level of 95% of the share capital.  Full Article

Ablynx NV And Merck KGaA's Merck Serono Further Strengthen Their Collaboration On Co-discovery And Co-development Of Nanobodies
Thursday, 26 Sep 2013 01:31am EDT 

Ablynx NV and Merck Serono, the biopharmaceutical division of Merck KGaA, announced that they have further expanded their relationship through a multi-year research alliance that could lead to at least four co-discovery and co-development collaborations. Under the terms of the agreement, Merck Serono will fund a dedicated discovery group at Ablynx. Both partners will jointly select disease targets against which this group will develop Nanobodies, up to in vivo proof-of-principle. The dedicated group will focus on the discovery and development of Nanobodies against a number of targets across multiple disease areas. The collaboration will span all of Merck Serono's core research and development fields, including oncology, immuno-oncology, immunology and neurology.  Full Article

Merck KGaA Reaffirms FY 2013 Guidance-Conference Call
Tuesday, 6 Aug 2013 08:00am EDT 

Merck KGaA confirmed guidance for fiscal 2013 and expects sales to be in the range of EUR10.7 billion to EUR10.9 billion, EBITDA pre to be in the range of EUR3.1 billion to EUR3.2 billion and EPS to be in the range of EUR8.50 to EUR9.00.  Full Article

BlackRock Inc Increases Stake In Merck KGaA-DJ
Monday, 8 Jul 2013 05:15am EDT 

Dow Jones reported that Merck KGaA said U.S. asset manager BlackRock Inc has increased its stake in the Company and exceeded the threshold of 10% in Merck voting rights on July 3. At that time, BlackRock held 6,464,198 voting rights, which is just over 10%, Merck said.  Full Article

BRIEF-Morphosys enters strategic immuno-oncology collaboration with Merck Serono

FRANKFURT, June 12 - Morphosys AG : * Says enters strategic immuno-oncology collaboration * Says Morphosys and Merck Serono enter strategic immuno-oncology collaboration

Search Stocks